Free Trial

Aclaris Therapeutics (ACRS) News Today

Aclaris Therapeutics logo
$1.44 +0.06 (+4.35%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.44 +0.01 (+0.35%)
As of 05/2/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Aclaris Therapeutics, Inc. stock logo
217,265 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Purchased by 683 Capital Management LLC
683 Capital Management LLC acquired a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 217,265 shares of the biotechnology company's stock, va
Aclaris Therapeutics, Inc. stock logo
RA Capital Management L.P. Purchases New Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
RA Capital Management L.P. acquired a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,666,667 shares of the biotechnology company's stock, valu
Aclaris Therapeutics, Inc. stock logo
888,888 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Acquired by Monashee Investment Management LLC
Monashee Investment Management LLC purchased a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 888,888 shares of the biotechnology company's stock, valued at app
Aclaris Therapeutics, Inc. stock logo
Samsara BioCapital LLC Buys 1,688,889 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Samsara BioCapital LLC increased its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 242.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,385,060 shares of the biotech
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 34.8% in April
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 4,070,000 shares, a drop of 34.8% from the March 31st total of 6,240,000 shares. Based on an average trading volume of 902,300 shares, the short-interest ratio is presently 4.5 days. Currently, 6.1% of the company's stock are sold short.
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics (ACRS) Expected to Announce Earnings on Tuesday
Aclaris Therapeutics (NASDAQ:ACRS) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-aclaris-therapeutics-inc-stock/)
Aclaris Therapeutics, Inc. stock logo
2,266,667 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Bought by Decheng Capital LLC
Decheng Capital LLC purchased a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,266,667 shares of the biotechnology company's
Aclaris Therapeutics, Inc. stock logo
Adage Capital Partners GP L.L.C. Buys Shares of 9,627,304 Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Adage Capital Partners GP L.L.C. bought a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 9,627,304 shares of the biotechnology company's stock, valued at approxima
Aclaris Therapeutics, Inc. stock logo
Renaissance Technologies LLC Sells 520,181 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Renaissance Technologies LLC reduced its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 38.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 850,519 shares of the biotechnology company's stock after selling 520,1
Aclaris Therapeutics, Inc. stock logo
Marshall Wace LLP Takes $6.53 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Marshall Wace LLP acquired a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,634,065 shares of the biotechnology
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from Analysts
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average rating of "Buy" by the eight analysts that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recomm
Aclaris Therapeutics, Inc. stock logo
Rock Springs Capital Management LP Has $15.39 Million Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Rock Springs Capital Management LP increased its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 125.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,204,309 shares of the b
Aclaris Therapeutics, Inc. stock logo
Vivo Capital LLC Invests $22.04 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Vivo Capital LLC acquired a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 8,888,888 shares of the biotechnology company's
Aclaris Therapeutics, Inc. stock logo
Walleye Capital LLC Acquires Shares of 718,897 Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Walleye Capital LLC bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 718,897 shares of the biotechnology company's stock, valued at a
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 6,030,000 shares, an increase of 26.7% from the February 28th total of 4,760,000 shares. Approximately 9.0% of the company's shares are short sold. Based on an average daily volume of 933,400 shares, the days-to-cover ratio is currently 6.5 days.
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have earned an average rating of "Buy" from the eight brokerages that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy ratin
Aclaris Therapeutics, Inc. stock logo
Cantor Fitzgerald Issues Negative Forecast for ACRS Earnings
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Aclaris Therapeutics in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earn
Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by Cantor Fitzgerald
Cantor Fitzgerald began coverage on shares of Aclaris Therapeutics in a research note on Tuesday. They set an "overweight" rating on the stock.
Aclaris Therapeutics, Inc. stock logo
Connor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Connor Clark & Lunn Investment Management Ltd. lifted its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 173.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 908,819 shares of the biotechnology company's stock after
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics (NASDAQ:ACRS) Stock Crosses Below 50-Day Moving Average - Should You Sell?
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Crosses Below 50 Day Moving Average - Here's Why
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at Scotiabank
Scotiabank assumed coverage on shares of Aclaris Therapeutics in a report on Friday. They issued a "sector outperform" rating and a $15.00 price target on the stock.
Aclaris Therapeutics initiated with an Outperform at Scotiabank
Aclaris Therapeutics, Inc. stock logo
Research Analysts Set Expectations for ACRS FY2025 Earnings
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal expects
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Strong-Buy at Cantor Fitzgerald
Cantor Fitzgerald raised shares of Aclaris Therapeutics to a "strong-buy" rating in a report on Tuesday.
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Buy" from Analysts
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been assigned an average rating of "Buy" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy
Aclaris Therapeutics, Inc. stock logo
Q1 Earnings Forecast for ACRS Issued By Leerink Partnrs
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research note issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith expects that the
Aclaris Therapeutics files $300M mixed securities shelf
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.
Aclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c)
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics (NASDAQ:ACRS) Share Price Passes Below Fifty Day Moving Average - Here's Why
Aclaris Therapeutics (NASDAQ:ACRS) Share Price Passes Below 50-Day Moving Average - Should You Sell?
Piper Sandler Remains a Buy on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics (ACRS) Projected to Post Earnings on Tuesday
Aclaris Therapeutics (NASDAQ:ACRS) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.
Aclaris Therapeutics, Inc. stock logo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 15.6% in January
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,920,000 shares, an increase of 15.6% from the January 15th total of 3,390,000 shares. Based on an average trading volume of 2,400,000 shares, the short-interest ratio is presently 1.6 days.
Aclaris Therapeutics, Inc. stock logo
Peapod Lane Capital LLC Invests $1 Million in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Peapod Lane Capital LLC bought a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 404,452 shares of the biotechnology company's stock, valued at approxi
Get Aclaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

ACRS Media Mentions By Week

ACRS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACRS
News Sentiment

1.12

0.73

Average
Medical
News Sentiment

ACRS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACRS Articles
This Week

11

3

ACRS Articles
Average Week

Get Aclaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ACRS) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners